ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 61 citations in OpenAlex.
- Age-Stratified Analysis of Blood-Brain Barrier Proteins Identifies Lower Occludin Abundance in the 3xTg-AD Model.International journal of molecular sciences · 2026Article
- The concurrent burden of Alzheimer's pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline.The journal of prevention of Alzheimer's disease · 2026Article
- Aggregation in gut: on the link between neurodegeneration and bacterial functional amyloids.NPJ biofilms and microbiomes · 2026Article
- Integrative epigenomic landscape of Alzheimer's Disease brains reveals oligodendrocyte molecular perturbations associated with tau.Nature communications · 2026Article
- Brain multiomic profiling identifies tau-related transcriptomic dysregulation in Alzheimer's disease.Brain communications · 2026Article
- Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS).American journal of epidemiology · 2025Article
- Cerebrovascular disease in Alzheimer's disease: Brain structure as a critical mediator of cognitive decline.The journal of prevention of Alzheimer's disease · 2025Article
- Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.Journal of neuroinflammation · 2025Article
- Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Single-Nucleus Landscape of Glial Cells and Neurons in Alzheimer's Disease.Molecular neurobiology · 2025Article
- A study on the effect of blue light on kidney stone formation in rats via the brain-kidney axis.Scientific reports · 2025Article
- Protection of Alzheimer's disease progression by a human-origin probiotics cocktail.Scientific reports · 2025Article
- The UFMylation pathway is impaired in Alzheimer's disease.Molecular neurodegeneration · 2024Article
- APOE 𝜀4-related blood-brain barrier breakdown is associated with microstructural abnormalities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Decreased microvascular claudin-5 levels in cerebral amyloid angiopathy associated with intracerebral haemorrhage.Brain pathology (Zurich, Switzerland) · 2024Article
- Challenges and Future Perspectives in Modeling Neurodegenerative Diseases Using Organ-on-a-Chip Technology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Effect of Apolipoprotein E isoforms on the Abundance and Function of P-glycoprotein in Human Brain Microvascular Endothelial Cells.Pharmaceutical research · 2024Article
- The UFMylation pathway is impaired in Alzheimer's disease.bioRxiv : the preprint server for biology · 2024Article
- Early- and Late-Onset Alzheimer's Disease: Two Sides of the Same Coin?Diseases (Basel, Switzerland) · 2024Review
- Neuropathogenesis-on-chips for neurodegenerative diseases.Nature communications · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 3 institutions in 1 country.
Funding
Abstract
introductionCerebrovascular pathologies including cerebral amyloid angiopathy (CAA) and blood-brain barrier (BBB) dysregulation are prominent features in the majority of Alzheimer's disease (AD) cases.
methodsWe performed neuropathologic and biochemical studies on a large, neuropathologically confirmed human AD cohort (N = 469). Amounts of endothelial tight junction proteins claudin-5 (CLDN5) and occludin (OCLN), and major AD-related molecules (amyloid beta [Aβ40], Aβ42, tau, p-tau, and apolipoprotein E) in the temporal cortex were assessed by ELISA.
resultsHigher levels of soluble tau, insoluble p-tau, and apolipoprotein E (apoE) were independently correlated with lower levels of endothelial tight junction proteins CLDN5 and OCLN in AD brains. Although high Aβ40 levels, APOE ε4, and male sex were predominantly associated with exacerbated CAA severity, those factors did not influence tight junction protein levels. DISCUSSION: Refining the molecular mechanisms connecting tau, Aβ, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.